# MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

> **NCT04762199** · PHASE1 · RECRUITING · sponsor: **Emory University** · enrollment: 69 (estimated)

## Conditions studied

- Advanced Lung Non-Small Cell Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DRUG:** Flt3/MerTK Inhibitor MRX-2843
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT04762199
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-02-24
- **Primary completion:** 2026-12-27
- **Final completion:** 2026-12-27
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04762199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04762199, "MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04762199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*